Skip to main content
. 2021 Apr 22;21(6):489. doi: 10.3892/ol.2021.12749

Figure 1.

Figure 1.

Schematic representation of the study design. miRNA, microRNA; FP, fluoropyrimidine; OX, oxaliplatin; BEV, bevacizumab; PR, partial response; PD, progression disease.